Pharma-Bio Serv, Inc.
PBSV
$0.60
-$0.09-13.03%
OTC PK
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -18.82% | 1.66% | 3.83% | -35.15% | -47.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.82% | 1.66% | 3.83% | -35.15% | -47.17% |
| Cost of Revenue | -22.10% | -9.14% | -7.67% | -39.79% | -41.11% |
| Gross Profit | -9.62% | 32.37% | 43.41% | -21.85% | -59.01% |
| SG&A Expenses | -12.69% | -1.60% | -11.66% | -10.28% | -6.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.68% | -6.53% | -9.05% | -31.85% | -31.99% |
| Operating Income | 17.78% | 68.63% | 78.96% | -197.49% | -182.91% |
| Income Before Tax | 27.98% | 152.39% | 103.76% | 69.04% | -149.40% |
| Income Tax Expenses | -125.26% | -74.06% | -91.47% | -4,328.57% | -68.95% |
| Earnings from Continuing Operations | 33.93% | 144.62% | 103.14% | 134.18% | -158.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.93% | 144.62% | 103.14% | 134.18% | -158.76% |
| EBIT | 17.78% | 68.63% | 78.96% | -197.49% | -182.91% |
| EBITDA | 20.97% | 74.18% | 80.79% | -233.78% | -179.93% |
| EPS Basic | 34.07% | 145.16% | 103.39% | 133.33% | -158.95% |
| Normalized Basic EPS | 27.85% | 151.92% | 104.29% | 69.23% | -149.38% |
| EPS Diluted | 35.71% | 143.01% | 103.33% | 133.33% | -161.14% |
| Normalized Diluted EPS | 27.85% | 151.92% | 104.29% | 69.23% | -149.38% |
| Average Basic Shares Outstanding | -0.15% | -0.12% | -0.02% | -0.11% | -0.02% |
| Average Diluted Shares Outstanding | -0.10% | -0.11% | -0.11% | -0.11% | -0.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 3.24% | -- | -- | -- |